High incidence and geographic distribution of cleft palate cases in Finland are associated with a regulatory variant in

Fedik Rahimov,Pekka Nieminen,Priyanka Kumari,Emma Juuri,Tiit Nikopensius,Kitt Paraiso,Jakob German,Antti Karvanen,Mart Kals,Abdelrahman G Elnahas,Juha Karjalainen,Mitja Kurki,Aarno Palotie,FinnGen,Estonian Biobank Research Team,Arja Heliovaara,Tonu Esko,Sakari Jukarainen,Priit Palta,Andrea Ganna,Anjali P Patni,Daniel Mar,Karol Bomsztyk,Julie Mathieu,Hannele Ruohola-Baker,Axel Visel,Walid D Fakhouri,Brian C Schutte,Robert A Cornell,David P Rice

DOI: https://doi.org/10.1101/2024.07.09.24310146

2024-07-10

Abstract:In Finland the frequency of isolated cleft palate (CP) is higher than that of isolated cleft lip with or without cleft palate (CL/P). This trend contrasts to that in other European countries but its genetic underpinnings are unknown. We performed a genome-wide association study for orofacial clefts, which include CL/P and CP, in the Finnish population. We identified rs570516915, a single nucleotide polymorphism that is highly enriched in Finns and Estonians, as being strongly associated with CP ( = 5.25 × 10 , OR = 8.65, 95% CI 6.11-12.25), but not with CL/P ( = 7.2 × 10 ), with genome-wide significance. The risk allele frequency of rs570516915 parallels the regional variation of CP prevalence in Finland, and the association was replicated in independent cohorts of CP cases from Finland ( = 8.82 × 10 ) and Estonia ( = 1.25 × 10 ). The risk allele of rs570516915 disrupts a conserved binding site for the transcription factor IRF6 within a previously characterized enhancer upstream of the gene. Through reporter assay experiments we found that the risk allele of rs570516915 diminishes the enhancer activity. Oral epithelial cells derived from CRISPR-Cas9 edited induced pluripotent stem cells demonstrate that the CP-associated allele of rs570516915 concomitantly decreases the binding of IRF6 and the expression level of , suggesting impaired autoregulation as a molecular mechanism underlying the risk for CP.

Genetic and Genomic Medicine